Sign In
Buy RIGL
$30.30
+0.280 (+0.93%)
At Close: Jun 03, 2026
Rigel Provides Business Update and 2026 Outlook
08:05am, Monday, 12'th Jan 2026
Preliminary fourth quarter 2025 total revenue of approximately $69.8 million, including net product sales of $65.4 million and contract revenues of $4.4 million In the dose escalation phase of the Pha
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08:05am, Friday, 09'th Jan 2026
SOUTH SAN FRANCISCO, Calif., Jan. 9, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. In
5 Small Drug Stocks to Buy as Industry Recovery Picks Up
09:46am, Wednesday, 07'th Jan 2026
Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions to one's portfolio.
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference
08:05am, Wednesday, 07'th Jan 2026
SOUTH SAN FRANCISCO, Calif., Jan. 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today annou
Best Momentum Stocks to Buy for January 6th
11:01am, Tuesday, 06'th Jan 2026
RIGL, CM and NMTC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 6th, 2026.
New Strong Buy Stocks for January 6th
06:35am, Tuesday, 06'th Jan 2026
ILPT, NMTC, RIGL, RIO and BHP have been added to the Zacks Rank #1 (Strong Buy) List on January 6th, 2026.
Rigel Pharma: Formulating A Game Plan For 2026
04:41am, Thursday, 01'st Jan 2026
Rigel Pharmaceuticals delivered strong 2025 results, with Q3 revenue of $69.5M, net income of $27.9M, and cash of $137.1M. RIGL raised 2025 revenue guidance to $285M–$290M, projecting 55%–59% comm
Rigel Pharmaceuticals, Inc. $RIGL Position Boosted by Squarepoint Ops LLC
05:40am, Wednesday, 24'th Dec 2025
Squarepoint Ops LLC increased its position in Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) by 64.0% in the second quarter, according to its most recent disclosure with the SEC. The institutional investo
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of “Hold” from Analysts
01:42am, Friday, 19'th Dec 2025
Shares of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL - Get Free Report) have received an average rating of "Hold" from the seven research firms that are covering the stock, Marketbeat reports. Four res
R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patients RBC-TI was achieved by 33% (6/18) o
Rigel Pharmaceuticals (RIGL) is a Great Momentum Stock: Should You Buy?
01:01pm, Friday, 05'th Dec 2025
Does Rigel Pharmaceuticals (RIGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Should Value Investors Buy Rigel Pharmaceuticals (RIGL) Stock?
10:41am, Wednesday, 03'rd Dec 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Rigel Pharmaceuticals, Inc. (RIGL) Hit a 52 Week High, Can the Run Continue?
10:16am, Thursday, 27'th Nov 2025
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Rigel Pharma: Q3 Earnings Showcase Robust Growth
08:15am, Wednesday, 26'th Nov 2025
Rigel Pharma is a profitable biotech with three FDA-approved drugs, experiencing accelerating revenue growth led by Tavalisse's strong performance. RIGL trades at a significant discount to biotech pee
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference
08:05am, Wednesday, 26'th Nov 2025
SOUTH SAN FRANCISCO, Calif. , Nov. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today ann
